ENDRA Life Sciences Inc. (NASDAQ:NDRA) Short Interest Up 43.5% in March

ENDRA Life Sciences Inc. (NASDAQ:NDRA) was the target of a large increase in short interest in the month of March. As of March 15th, there was short interest totalling 40,600 shares, an increase of 43.5% from the February 28th total of 28,300 shares. Based on an average trading volume of 19,800 shares, the short-interest ratio is presently 2.1 days. Approximately 7.6% of the shares of the stock are short sold.

ENDRA Life Sciences Stock Performance

NDRA stock traded down $0.12 during midday trading on Tuesday, hitting $3.98. 4,049 shares of the stock were exchanged, compared to its average volume of 99,393. The stock’s 50-day moving average price is $4.59 and its 200-day moving average price is $5.94. The stock has a market cap of $2.14 million, a price-to-earnings ratio of 0.00 and a beta of 0.43. ENDRA Life Sciences has a fifty-two week low of $3.15 and a fifty-two week high of $717.50.

ENDRA Life Sciences (NASDAQ:NDRA) last released its quarterly earnings data on Monday, March 31st. The company reported ($9.40) EPS for the quarter, missing the consensus estimate of ($4.10) by ($5.30). Research analysts anticipate that ENDRA Life Sciences will post -47.46 EPS for the current year.

ENDRA Life Sciences Company Profile

ENDRA Life Sciences Inc develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is developing thermo-acoustic enhanced ultrasound technology that uses radio frequency pulses to generate ultrasonic waves in tissue to create high-contrast images for use in the treatment of nonalcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion.